Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July
Mina Sooch CEO to Present at Ophthalmic Innovation Panel at the 11th Annual AECOS Summer Symposium and OIS Retina Innovation Summit ASRS Late-Breaking...
Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication
Newly Issued Patent Broadens Medical Uses of Oral APX3330 Therapy in Patients with Diabetes and Extends Expiry Thru 2038 Peer-Reviewed Publication...
Ocuphire Announces Positive Topline Results from LYNX-1 Phase 3 Trial Evaluating Nyxol® Eye Drops for Night Vision Disturbances
Met FDA-agreed Primary Endpoint with More Nyxol Subjects Gaining 3 Lines of Low Contrast Distance Vision under Dim Light Conditions Compared to Placebo ...